Channelopathies

Subscribe to Selected New Research on Channelopathies

310 relevant articles (4 outcomes, 15 trials/studies) found for this Disease

Description: A variety of neuromuscular conditions resulting from MUTATIONS in ION CHANNELS manifesting as episodes of EPILEPSY; HEADACHE DISORDERS; and DYSKINESIAS.

Also Known As:

Channelopathy

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Pathologic Processes: 2205

Channelopathies: 310

Related Diseases

1.	Epilepsy (Aura)
2.	Ataxia (Dyssynergia)
3.	Temporal Lobe Epilepsy
4.	Anorexia Nervosa
5.	Paralysis (Palsy)
91 Diseases and 167 more articles analyzed in the Research Interface, order at left...

Experts

1.	Lory, Philippe: 2 articles (07/2008 - 12/2006)
2.	Watanabe, Osamu: 2 articles (01/2006 - 01/2002)
3.	Arimura, Kimiyoshi: 2 articles (01/2006 - 01/2002)
4.	Balser, Jeffrey R: 2 articles (01/2004 - 04/2002)
5.	Nattel, S: 2 articles (02/2001 - 11/2000)
6.	Noebels, Jeffrey: 1 article (07/2008)
7.	Perez-Reyes, Edward: 1 article (07/2008)
8.	Shuba, Yaroslav M: 1 article (07/2008)
9.	Schneider, T: 1 article (04/2008)
10.	Weiergräber, M: 1 article (04/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Channelopathies:

1.	CalciumIBA 01/01/1998 - "The preliminary studies of the recently discovered calcium channelopathies are undergoing" 04/01/2008 - "Human calcium channelopathies" 10/01/2007 - "Research about calcium channelopathies should clarify how altered channel function produces disease and lead to new treatments for these conditions." 12/01/2006 - "Calcium channelopathies: the current challenges]" 11/01/2006 - "During the past decade, our understanding of the gating and functions of VGCCs has been illuminated by the analysis of mutations linked to a heterogeneous group of genetic diseases called "calcium channelopathies"" Get all the results and reference details, order at left...
2.	Calcium Channels (Calcium Channel)IBA 01/01/1998 - "Complementary studies are necessary to identify the precise implication of calcium channels in these auto-immune channelopathies." 01/01/2007 - "At least in those instances wherein the channelopathies can be attributed to gain-of-function mechanisms, the data point towards new therapeutic strategies for developing highly selective calcium channel antagonists." 07/01/2006 - "Here we document our current understanding of the mutations underlying channelopathies involving the voltage-gated calcium channel alpha subunits in humans and other species." 02/01/2002 - "Calcium channels and channelopathies of the central nervous system." 11/01/1999 - "Changes in the electrophysiologic properties of the mutated forms of the CACNL1A4 calcium channel expressed in heterologous systems help establish the functional significance of the mutations and suggest that chromosome 19p-linked FHM, an episodic disorder, represents a CNS channelopathy" Get all the results and reference details, order at left...
3.	PotassiumIBA 06/01/2008 - "Thus, new patents have been created allowing the prediction of the inherited predisposition to any known potassium-linked cardiac channelopathy." 04/01/2007 - "In most cases, the diagnosis of muscle channelopathy is still made on clinical grounds, but is supported by ancillary laboratory and electrodiagnostic testing such as serum potassium measurement, exercise testing, repetitive nerve stimulation, needle electromyography, calculation of muscle fiber conduction velocity, or electromyography power spectra" 01/01/2006 - "Molecular mechanisms of cardiac voltage-gated potassium channelopathies." 01/01/2006 - "Immune-mediated potassium channelopathies." 05/01/2004 - "It is a potassium channelopathy due to mutation of KCJN2 gene coding for Kir 2.1 protein" Get all the results and reference details, order at left...
4.	Carbamazepine (Tegretol)FDA LinkGeneric 08/07/2007 - "CONCLUSIONS: Paroxysmal extreme pain disorder is a highly distinctive sodium channelopathy with incompletely carbamazepine-sensitive bouts of pain and sympathetic nervous system dysfunction" 11/01/2008 - "Findings propose that potassium ion channelopathy may underlie disease for a group of infants or young children displaying idiopathic megalencephaly and early onset epilepsy or episodic ataxia type 1. Carbamazepine's remarkable protective effects on the neuronal plasticity in the hyperexcitable state should be further studied, and maybe this drug should be considered more in treatment of temporal lobe epilepsy and megalencephaly." Get all the results and reference details, order at left...
5.	Anticonvulsants (Antiepileptic Drugs)IBA 09/06/2005 - "The concept of channelopathies is in keeping with some characteristics of anorexia nervosa, such as a genetically-based predisposition to hypophagia, early onset, cardiac abnormalities, an appetite-enhancing efficacy of some antiepileptic drugs, and others" 04/01/2007 - "Despite this, the recognition that the idiopathic epilepsies are a group of channelopathies has, to a limited extent, explained the therapeutic action of the common antiepileptic drugs and has assisted clinical diagnosis of some epilepsy syndromes." Get all the results and reference details, order at left...
6.	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA 01/01/2006 - "Carbonic-anhydrase inhibitors are effective in channelopathies possibly by opening the Ca2+-activated-K+ channels" Get all the results and reference details, order at left...
7.	Carbonic Anhydrase InhibitorsIBA 01/01/2006 - "Carbonic-anhydrase inhibitors are effective in channelopathies possibly by opening the Ca2+-activated-K+ channels" Get all the results and reference details, order at left...
8.	Ion Channels (Ion Channel)IBA 12/01/2006 - "Recently, more and more studies have discovered that some diseases result from gene defect and functional variation of ion channels, known as ion channelopathies" 06/01/2004 - "Recently, more and more studies have discovered that some diseases result from gene defect and functional variation of ion channels, which are called ion passage diseases or ion channelopathies" 01/01/2001 - "CONCLUSIONS: Studies of human inherited channelopathies have clarified the functions of many ion channels" 06/01/2000 - "Biophysical studies of mutant ion channels in vitro allow detailed investigations of the basic mechanism underlying these 'channelopathies'" 06/01/2008 - "Mutations in genes that encode ion channels have been identified to cause various diseases and disorders known as channelopathies" Get all the results and reference details, order at left...
9.	Sodium Channels (Sodium Channel)IBA 10/01/2007 - "Magnetic resonance spectroscopy now provides an exciting opportunity to visualize metabolic changes and the pathophysiologically relevant cellular perturbations in muscle channelopathies affecting the muscle-specific sodium-channel isoform Na(v)1.4" 04/01/2007 - "What is the relationship between sodium channel function, neuronal function and clinical status in channelopathies of the nervous system" 06/26/2001 - "Emerging evidence also suggests that an acquired channelopathy, characterized by abnormal expression of sensory neuron specific sodium channels that can alter impulse trafficking within Purkinje cells, may contribute to the pathophysiology of MS. Subtype-specific drugs that selectively modulate various types of channels probably will soon be developed" 06/26/2001 - "Recent research has established that peripheral nerve injury can provoke an acquired channelopathy in spinal sensory neurons; axonal transection triggers the turning-off of some previously active sodium channel genes and the turning-on of at least one previously silent sodium channel gene, a set of molecular changes that can result in hyperexcitability of these cells" 06/26/2001 - "Dysregulated expression of sodium channels due to alterations in activity of nonmutated channel genes, on the other hand, can produce acquired channelopathies" Get all the results and reference details, order at left...
10.	SodiumIBA 11/01/2008 - "SCNM1 was first identified as a modifier of the severity of a sodium channelopathy in the mouse" 02/01/2008 - "Our observation expands the phenotypic spectrum of sodium channelopathies." 01/01/2008 - "Clinical heterogeneity in sodium channelopathies" 04/01/2007 - "Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype." 12/07/2006 - "PEPD and PE are allelic variants with distinct underlying biophysical mechanisms and represent a separate class of peripheral neuronal sodium channelopathy." Get all the results and reference details, order at left...
102 Drugs and Important Bio-Agents and 304 more articles analyzed in the Research Interface, order at left...

Therapies and Procedures

1.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 10/01/2006 - "Part II: ventricular arrhythmias, channelopathies and implantable defibrillators." 08/01/2006 - "A related document discusses ventricular arrhythmias, channelopathies and implantable cardioverter defibrillators." 10/01/2004 - "This article focuses on implantable cardioverter-defibrillator (ICD) therapy in the child/adolescent who is predisposed to sudden cardiac death because of an underlying channelopathy" 10/01/2004 - "Sudden cardiac death and channelopathies: a review of implantable defibrillator therapy." 01/01/2005 - "High-risk patients (recurrent syncope and sudden cardiac death survivors) with inherited ion channelopathies benefit from implantable cardioverter-defibrillator placement" Get all the results and reference details, order at left...
2.	Drug Therapy (Chemotherapy) 04/01/2008 - "This review provides a comprehensive review of the molecular genetics, clinical features, genotype-phenotype correlations and genotype-specific approach to pharmacotherapy of these two mirror-image channelopathies, SQTS and LQTS." 04/01/2008 - "Defining the molecular basis of channelopathies can have a profound impact on patient management, particularly in cases in which genotype-specific pharmacotherapy is available" 01/10/2002 - "Recognizing the fundamental defects in channelopathies provides the basis for new strategies of treatment, including tailored pharmacotherapy and gene therapy." 03/01/2007 - "KATP channelopathies usually produce microscopic intra-pancreatic lesions and are typically unresponsive to drug therapy, requiring > 95% pancreatectomy for diffuse disease and occasionally more limited pancreatic resection for focal disease; macroscopic pancreatic lesions and adenomas are focally excised" Get all the results and reference details, order at left...
3.	Plasma Exchange 04/01/2007 - "Treatment of autoimmune channelopathies includes drugs that help restore normal neuronal function and treatments to remove pathogenic antibodies (plasma exchange) or modulate the immune response (steroids or immunosuppressants)" Get all the results and reference details, order at left...
4.	Pancreatectomy 03/01/2007 - "KATP channelopathies usually produce microscopic intra-pancreatic lesions and are typically unresponsive to drug therapy, requiring > 95% pancreatectomy for diffuse disease and occasionally more limited pancreatic resection for focal disease; macroscopic pancreatic lesions and adenomas are focally excised" Get all the results and reference details, order at left...
4 Therapies and Procedures and 9 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>